

Enhancer of zeste homolog 2 protein inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/EC256E6F8F86EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: EC256E6F8F86EN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Enhancer of zeste homolog 2 protein inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Enhancer of zeste homolog 2 protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Enhancer of zeste homolog 2 protein inhibitors Understanding

Enhancer of zeste homolog 2 protein inhibitors: Overview

Enhancer of zeste homolog 2 is a component of the Polycomb repressive complex 2 that mediates chromatin-based gene silencing through trimethylation of lysine 27 on histone H3. This complex plays vital roles in the regulation of development-specific gene expression.

Function – Enhancer of zeste homolog 2 (EZH2) is a histone-lysine N-methyltransferase enzyme encoded by EZH2 gene, that participates in histone methylation and, ultimately, transcriptional repression. EZH2 catalyzes the addition of methyl groups to histone H3

at lysine 27, by using the cofactor S-adenosyl-L-methionine. Mutation or over-expression of EZH2 has been linked to many forms of cancer. EZH2 inhibits genes responsible for suppressing tumor development, and blocking EZH2 activity may slow tumor growth. EZH2 has been targeted for inhibition because it is up regulated in multiple cancers.

Enhancer of zeste homolog 2 protein inhibitors – EZH2 is upregulated in various cancers with high levels associated with metastatic cancer and poor prognosis. Dysregulation of the histone methyltransferase EZH2 plays a critical role in the development of a variety of malignancies including B-cell lymphomas.

Enhancer of zeste homolog 2 protein inhibitors Emerging Drugs Chapters

This segment of the Enhancer of zeste homolog 2 protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Enhancer of zeste homolog 2 protein inhibitors Emerging Drugs

Tazemetostat: Epizyme, Inc.

Tazemetostat is a potent, selective, and orally bioavailable small-molecule inhibitor of EZH2 enzymatic activity. EZH2, a methyltransferase plays a role in epithelioid sarcoma pathogenesis. The drug is currently being evaluated in Phase III stage of development for the treatment of patients with Synovial cancer and various other solid tumors.

CPI-1205: Constellation Pharmaceuticals

CPI-1205 is a potent, selective EZH2 inhibitor that reduces global histone H3K27 trimethylation in a reversible way. The drug is currently being evaluated in Phase I/II stage of development in combination with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration-resistant prostate cancer.

Further product details are provided in the report.....

Enhancer of zeste homolog 2 protein inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Enhancer of zeste homolog 2 protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Enhancer of zeste homolog 2 protein inhibitors

There are approx. 10+ key companies which are developing the Enhancer of zeste homolog 2 protein inhibitors. The companies which have their Enhancer of zeste homolog 2 protein inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Epizyme Inc.

Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Enhancer of zeste homolog 2 protein inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Oral

Parenteral

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Enhancer of zeste homolog 2 protein inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Enhancer of zeste homolog 2 protein

inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Enhancer of zeste homolog 2 protein inhibitors drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Enhancer of zeste homolog 2 protein inhibitors R&D. The therapies under development are focused on novel approaches for Enhancer of zeste homolog 2 protein inhibitors.

Enhancer of zeste homolog 2 protein inhibitors Report Insights

Enhancer of zeste homolog 2 protein inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Enhancer of zeste homolog 2 protein inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Enhancer of zeste homolog 2 protein inhibitors drugs?

How many Enhancer of zeste homolog 2 protein inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Enhancer of zeste homolog 2 protein inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Enhancer of zeste homolog 2 protein inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Enhancer of zeste homolog 2 protein inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

Contents

Introduction

Executive Summary

Enhancer of zeste homolog 2 protein inhibitors: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Enhancer of zeste homolog 2 protein inhibitors – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Enhancer of zeste homolog 2 protein inhibitors companies' collaborations, Licensing, Acquisition -Deal Value Trends

Enhancer of zeste homolog 2 protein inhibitors Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Tazemetostat: Epizyme, Inc.

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

CPI-1205: Constellation Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

PF 06821497: Pfizer

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

OR S1: Daiichi Sankyo

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Enhancer of zeste homolog 2 protein inhibitors Key Companies

Enhancer of zeste homolog 2 protein inhibitors Key Products

Enhancer of zeste homolog 2 protein inhibitors- Unmet Needs

Enhancer of zeste homolog 2 protein inhibitors- Market Drivers and Barriers

Enhancer of zeste homolog 2 protein inhibitors- Future Perspectives and Conclusion

Enhancer of zeste homolog 2 protein inhibitors Analyst Views

Enhancer of zeste homolog 2 protein inhibitors Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Enhancer of zeste homolog 2 protein inhibitors

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Enhancer of zeste homolog 2 protein inhibitors

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Enhancer of zeste homolog 2 protein inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/EC256E6F8F86EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/EC256E6F8F86EN.html>